title: [Clinical experience of primaquine use for treatment of vivax and ovale malaria in Japanese travelers].
abstract: Primaquine phosphate has been used to prevent relapse as a radical cure after the acute-phase treatment of vivax and ovale malaria however. Many vivax malaria relapses have been reported following a standard dose of primaquine (15 mg/day for 14 days). A higher dose of primaquine (30 mg/day for 14 days) decreases the relapse rate, and the concomitant risk of gastrointestinal side effects tends to disappear when the drug is administered with food. G6PD deficiency is rare in the Japanese population. Although the relapsed phenomenon is reported globally, the higher dose of primaquine is currently recommended in Japan only for those returning from Southeast Asia or Papua New Guinea. Cases of 18 Japanese, including 13 vivax malaria and 5 ovale malaria, prescribed primaquine at a referral center in Japan, were analyzed retrospectively from 2007-2011. Data on diagnosis, treatment, and outcome were extracted from medical records. Of the 18, 10 with vivax malaria were administered the higher dose of primaquine. We found that only one suffered relapse-a vivax malarial case returning from Brazil and treated with the standard dose of primaquine. No ovale malarial case suffered relapse. None, including the 10 prescribed the higher primaquine dose, experienced any adverse side effects. Based on our findings, we recommend a higher dose of primaquine be used to prevent relapse when treating Japanese suffering from vivax malaria.
authors.affiliation: Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo Medical University Hospital.
authors.forename: Taiichiro
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Kato
authors.forename: Yuko
authors.initials: Y
authors.lastname: Yamauchi
authors.forename: Mugen
authors.initials: M
authors.lastname: Ujiie
authors.forename: Nozomi
authors.initials: N
authors.lastname: Takeshita
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Mizuno
authors.forename: Shuzo
authors.initials: S
authors.lastname: Kanagawa
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Kano
authors.forename: Norio
authors.initials: N
authors.lastname: Ohmagari
mesh_terms: D000328:Adult; D000962:Antimalarials / Q000627:therapeutic use*; D044466:Asian People; D005260:Female; D005955:Glucosephosphate Dehydrogenase Deficiency / Q000235:genetics; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011319:Primaquine / Q000627:therapeutic use*; D012189:Retrospective Studies; D055502:Secondary Prevention; D014195:Travel; D055815:Young Adult
chemical_list: D000962:Antimalarials; D011319:Primaquine